Pasar al contenido principal

FUNCION Y POTENCIAL TERAPEUTICO DE LAS HELICASAS DE RNA Y DE MIR-122A-5P EN LA REGENERACION HEPATICA Y EL CANCER

PID2022-138243OB-I00

•
Nombre agencia financiadora Agencia Estatal de Investigación
Acrónimo agencia financiadora AEI
Programa Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprograma Subprograma Estatal de Generación de Conocimiento
Convocatoria Proyectos de I+D+i (Generación de Conocimiento y Retos Investigación)
Año convocatoria 2022
Plan Estatal 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Centro beneficiario FUNDACIÓ DE RECERCA CLÍNIC BARCELONA-INSTITUT D'INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Tcf20 deficiency is associated with increased liver fibrogenesis and alterations in mitochondrial metabolism in mice and humans

  • Córdoba-Jover, Bernat
  • Ribera, Jordi
  • Portolés, Irene
  • Lecue, Elena
  • Rodriguez-Vita, Juan
  • Pérez-Sisqués, Leticia
  • Mannara, Francesco
  • Solsona-Vilarrasa, Estel
  • García-Ruiz, Carmen
  • Fernández-Checa, José C.
  • Casals, Gregori
  • Rodríguez-Revenga, Laia
  • Álvarez-Mora, María Isabel
  • Arteche-López, Ana
  • Díaz de Bustamante, Aranzazu
  • Calvo, Rosa
  • Pujol, Anna
  • Azkargorta, Mikel
  • Elortza, Felix
  • Malagelada, Cristina
  • Pinyol, Roser
  • Huguet-Pradell, Júlia
  • Melgar-Lesmes, Pedro
  • Jiménez, Wladimiro
  • Morales-Ruiz, Manuel
Transcription co-activator factor 20 (TCF20) is a regulator of transcription factors involved in extracellular matrix remodelling. In addition, TCF20 genomic variants in humans have been associated with impaired intellectual disability. Therefore, we hypothesized that TCF20 has several functions beyond those described in neurogenesis, including the regulation of fibrogenesis., We acknowledge the support from grants PDI2019-105502RB-100 and PID2022-138243OB-I00 to MM-R, PID2019-111669RB, BES-2017-080823 to IP "ESF Investing in your future", and RTI2018-094734-B-C21 to WJ and PM-L, from MCIN/AEI/10.13039/501100011033. RedFibro (RED2022-134485-T) of the 2022 caLL for aid to «RESEARCH NETWORKS», within the framework of the Programa Estatal del Plan Estatal de Investigación Científica, Técnica y de Innovación 2021–2023. Consolidated Research Group of the Generalitat de Catalunya AGAUR (2021 SGR 00881 to MM-R) and PM-L financed ESF Investing in your future, support from AGAUR of the Generalitat de Catalunya. Fundación Mutua Madrileña AP171442019, European Cooperation in Science & Technology (COST) ACTION CA17112 Prospective European Drug-Induced Liver Injury Network, and the Project 201 916/31 Contribution of mitochondrialoxysterol and bile acid metabolism to liver carcinogenesis 2019 by Fundació Marató TV3. PM-L was additionally supported by a fellowship from the Ramon y Cajal Program (RYC2018-0Z23971-I) and a grant (PID2021-123426OB-I00) from the Spanish Ministerio de Ciencia, Innovación y Universidades. CIBERehd is financed by the Instituto de Salud Carlos III., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Mesoporous Silica-Encapsulated Cerium Oxide Nanozymes and Quercetin for Synergistic ROS-Modulated Downregulation of Inflammatory Cytokines

  • Zhou, Shanlei
  • Zhang, Yu
  • Casals, Eudald
  • Zhang, Bo
  • Casals, Gregori
  • Zeng, Muling
  • Morales Ruiz, Manuel
  • Liu, Qingshi
Introduction: Combining natural antioxidants with nanozymes represents a promising strategy to enhance therapeutic outcomes in oxidative stress-related diseases. This study integrates quercetin (Que), a plant-derived flavonoid with strong antioxidant activity, and cerium oxide nanozymes (CeO<inf>2</inf> NZs) into mesoporous silica (mSiO<inf>2</inf>) to enhance therapeutic efficacy and overcome the poor solubility and bioavailability of natural antioxidants. Methods: Large-pore mSiO₂ (11 nm) were synthesized via a sol–gel method to encapsulate cerium oxide nanozymes (CeO₂NZs). Que was loaded using solvent impregnation to obtain (CeO₂/Que)@mSiO₂ nanocomposites. Structural and chemical characterization was performed, and biological evaluations were conducted in A549 cells. Results: The incorporation of a large mesopore mSiO₂ (11 nm) significantly enhanced Que loading capacity and its sustained release in cell culture media. The (CeO₂/Que)@mSiO₂ nanocomposite demonstrated excellent biocompatibility, effective ROS scavenging, and significant downregulation of inflammatory cytokines (IL-1β, IL-6, TNF-α) compared to free Que. Conclusion: The (CeO₂/Que)@mSiO₂ nanoplatform offers synergistic antioxidant and anti-inflammatory effects, supporting its potential for treating oxidative stress-related inflammatory conditions., This work was supported by grants from the Research Funding for Doctoral Talents of the First Affiliated Hospital of Anhui Medical University (grant No.1952); the Instituto de Salud Carlos III (PI24/00688 and BA22/00017 to G. C.), co-financed by FEDER, European Union, “A way of making Europe”; Agencia Estatal de Investigación (Project PID2022-138243OB-I00 funded by MICIU/AEI /10.13039/501100011033 and by FEDER, UE, to M.M.-R.). Consolidated Research Group, Departament de Recerca i Universitats de la Generalitat de Catalunya (2021 SGR 00881 to M.M.-R.). CIBERehd is financed by the Instituto de Salud Carlos III., With funding from the Spanish government through the ‘Severo Ochoa Centre of Excellence’ accreditation (CEX2023-001263-S)., Peer reviewed